Tamoxifeno e Espessamento Endometrial Assintomático

• Autor(es): Amaral, N ; Robalo, R ; Fatela, A
• Data: 2008
• Identificador Persistente: http://hdl.handle.net/10400.17/1330
• Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
• Assunto(s): Tamoxifeno; Estudos Retrospectivos; Diagnóstico
• Tipo de Documento: Artigo
• Idioma: Português

Descrição

Tamoxifen is a first-line agent for adjuvant treatment of estrogen-receptor positive breast cancer, and is used to reduce the risk of this condition in high-risk individuals. Retrospective studies established an association between tamoxifen use, endometrial thickness and endometrial cancer. There have been many attempts to identify an effective screening program for tamoxifen-related endometrial cancer, which have led to the use of transvaginal ultrasound and invasive procedures. The use of a 5mm endometrial cut-off in vaginal ultrasound is known to raise the number of endometrial biopsies with no gain in early cancer diagnosis. A review of the scientific literature was performed in order to establish the best available evidence for endometrial evaluation of asymptomatic breast cancer patients on tamoxifen.